Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate.
Tröger
U
U
Institute of Clinical Pharmacology, Hospital of the Otto-von-Guericke-University, D-39120 Magdeburg, Germany.
Stötzel
B
B
Martens-Lobenhoffer
J
J
Gollnick
H
H
Meyer
F P
FP
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001471:Barrett Esophagus / Q000188:drug therapy; D001562:Benzimidazoles / Q000009:adverse effects*; D003879:Dermatologic Agents / Q000009:adverse effects*; D004347:Drug Interactions; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced*; D009853:Omeprazole / Q000031:analogs & derivatives; D010146:Pain / Q000139:chemically induced*; D000077402:Pantoprazole; D013454:Sulfoxides / Q000009:adverse effects*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D003879:Dermatologic Agents; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole; D008727:Methotrexate